Triumeq

abacavir sulfate, dolutegravir sodium, lamivudine · Tablet, Film Coated · Oral

Prescription (Rx) Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor 1 recall

No FDA structured label text is available for Triumeq. The NDC listings below come from the FDA National Drug Code directory.

Active ingredients

Abacavir Sulfate in 1 product
Dolutegravir Sodium in 1 product
Lamivudine in 1 product

Triumeq NDC products (1)

NDC	Strength & form	Labeler	Type
49702-231	Abacavir Sulfate 600 mg/1; Dolutegravir Sodium 50 mg/1; Lamivudine 300 mg/1 Tablet, Film Coated	ViiV Healthcare Company	NDA

Triumeq recalls

D-0486-2021 Jun 2, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Frequently asked questions

Who makes Triumeq?

Triumeq is listed by 1 labeler in the FDA NDC directory, including ViiV Healthcare Company.

Has Triumeq been recalled?

The FDA enforcement database lists 1 recall for Triumeq, most recently D-0486-2021 (class ii): CGMP Deviations: Intermittent exposure to temperature excursion during storage.